Sunday, September 15, 2024 2:36:23 PM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent BHVN News
- Biohaven Shares Edge Higher After Completing Enrollment in Obesity Drug Trial • IH Market News • 03/19/2026 02:12:23 PM
- Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment • PR Newswire (US) • 03/19/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/13/2026 08:57:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/13/2026 08:54:52 PM
- uniQure shares jump 36% after news of FDA gene therapy chief’s departure • IH Market News • 03/09/2026 02:14:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 09:32:34 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/02/2026 09:30:08 PM
- Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results • PR Newswire (US) • 03/02/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 04:19:08 PM
- Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/12/2026 04:15:00 PM
- Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 • PR Newswire (US) • 01/07/2026 12:00:00 PM
- Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder • PR Newswire (US) • 12/24/2025 06:00:00 PM
- Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress • PR Newswire (US) • 12/11/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:27:36 PM
- Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M • PR Newswire (US) • 11/13/2025 09:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/13/2025 12:09:09 PM
- Biohaven Announces Pricing of $175 Million Public Offering of Common Shares • PR Newswire (US) • 11/12/2025 12:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 11:02:50 AM
- Biohaven Announces Proposed Public Offering of Common Shares • PR Newswire (US) • 11/11/2025 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/10/2025 01:11:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:02:00 PM
- Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments • PR Newswire (US) • 11/10/2025 11:58:00 AM
- FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia • PR Newswire (US) • 11/05/2025 01:06:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 10/30/2025 06:24:41 PM
- Shareholders that lost money on Biohaven Ltd.(BHVN) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 09/11/2025 12:45:00 PM

